Growth Hormone Injections and Insulin Resistance
Yes, growth hormone injections can worsen insulin resistance, particularly when high doses are used or when assessed during active GH exposure, though the effect is dose-dependent and timing-sensitive. 1
The Dose-Dependent Effect
The Endocrine Society Clinical Practice Guidelines explicitly state that GH therapy "tends to increase insulin resistance" in adults with growth hormone deficiency 1. However, the magnitude of this effect critically depends on dosing:
- High-dose GH: Insulin sensitivity deteriorates acutely through increased free fatty acid release and intramyocellular triglyceride accumulation 1
- Low-dose GH (given for 6-12 months): Causes no change in insulin sensitivity 1
- One study even showed improvement in HOMA index with appropriate dosing 1
The Mechanism: Direct Insulin Antagonism
GH has direct insulin antagonistic effects in the liver and other tissues 1. The mechanism involves:
- Suppression of pyruvate dehydrogenase activity in skeletal muscle 2, 3
- Increased lipolysis and free fatty acid levels 2
- Substrate competition between fatty acids and glucose 2
- Notably, this occurs without accumulation of diacylglycerols or ceramides and without impairing canonical insulin signaling 2
The Paradox: Opposing Forces
The net effect on insulin resistance is difficult to predict because GH has both beneficial and detrimental metabolic effects 1:
Beneficial effects:
- Reduces visceral and truncal fat mass
- Increases IGF-I, which improves insulin sensitivity
Detrimental effects:
- Direct insulin antagonism in liver and muscle
- Promotes lipolysis and free fatty acid release
Clinical Impact: Glucose Metabolism Changes
Meta-analyses demonstrate that GH therapy causes:
- Slight rise in fasting glucose levels (mean increase 0.58 mmol/L persisting after 4 years) 1
- Slight rise in fasting insulin levels 1
- In one placebo-controlled study, GH worsened glucose tolerance to impaired glucose tolerance in 13% and to diabetes in 4% of patients 1
Time-Dependent Reversibility
GH-induced insulin resistance is rapidly reversible 4. When GH infusion terminates 5 hours before insulin sensitivity assessment, the insulin resistance effect subsides 4. This means the timing of GH administration relative to meals and metabolic assessments matters clinically.
Newer Formulations
The once-weekly long-acting GH formulation somapacitan demonstrates neutral effects on glucose metabolism in clinical trials 5, suggesting that pharmacokinetic profiles may influence metabolic side effects.
Clinical Management Recommendations
For patients with diabetes mellitus, the Endocrine Society recommends that GH treatment may require adjustments in antidiabetic medications (strong recommendation) 1.
Key monitoring strategy:
- Start with low doses and titrate based on clinical response, side effects, and IGF-I levels 1
- Use individualized (not weight-based) dosing regimens 1
- Monitor glucose parameters regularly, especially in patients with pre-existing glucose intolerance
- Consider timing of GH administration relative to meals
Common Pitfalls to Avoid
- Using excessive doses: The insulin resistance effect is dose-dependent; higher doses cause more pronounced effects
- Ignoring individual variability: Some patients show worsening insulin sensitivity while others show little change 1
- Failing to monitor diabetic patients: Active surveillance and medication adjustment are necessary 1
- Not considering the timing effect: Acute GH exposure causes more insulin resistance than chronic low-dose therapy 4
Bottom Line for Clinical Practice
While GH can worsen insulin resistance through direct metabolic effects, this is manageable with appropriate low-dose regimens and monitoring. The benefits of GH replacement in true GH deficiency (improved body composition, cardiovascular markers, quality of life) generally outweigh the modest effects on glucose metabolism when dosed appropriately. However, patients with pre-existing diabetes or glucose intolerance require closer monitoring and potential adjustment of antidiabetic therapy 1.